BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Catalano F, Catanzaro R, Bentivegna C, Brogna A, Condorelli G, Cipolla R. Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. Aliment Pharmacol Ther. 1998;12:59-62. [PMID: 9692702 DOI: 10.1046/j.1365-2036.1998.00270.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Zullo A, Hassan C, Campo SM, Lorenzetti R, Febbraro I, De Matthaeis M, Porto D, Morini S. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther. 2001;15:1193-1197. [PMID: 11472322 DOI: 10.1046/j.1365-2036.2001.01028.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
2 Xia HH, Yu Wong BC, Talley NJ, Lam SK. Helicobacter pylori infection - current treatment practice. Expert Opinion on Pharmacotherapy 2005;2:253-66. [DOI: 10.1517/14656566.2.2.253] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
3 Gisbert JP, Calvet X, Gomollón F, Sáinz R. Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso. Medicina Clínica 2000;114:185-95. [DOI: 10.1016/s0025-7753(00)71237-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
4 Langtry HD, Wilde MI. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs. 1998;56:447-486. [PMID: 9777317 DOI: 10.2165/00003495-199856030-00012] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 3.2] [Reference Citation Analysis]
5 Catalano F, Branciforte G, Catanzaro R, Bentivegna C, Cipolla R, Nuciforo G, Brogna A. Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. Helicobacter. 1999;4:178-184. [PMID: 10469192 DOI: 10.1046/j.1523-5378.1999.99274.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter. 2005;10:157-171. [PMID: 15904473 DOI: 10.1111/j.1523-5378.2005.00307.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
7 Ren JM, Zou QM, Wang FK, He Q, Chen W, Zen WK. PELA microspheres loaded H. pylori lysates and their mucosal immune response. World J Gastroenterol 2002; 8(6): 1098-1102 [PMID: 12439933 DOI: 10.3748/wjg.v8.i6.1098] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
8 Catalano F, Catanzaro R, Branciforte G, Bentivegna C, Cipolla R, Brogna A, Nuciforo G. Five-day Triple Therapy in Helicobacter pylori-positive Duodenal Ulcer: An Eighteen-month Follow-up. Journal of Clinical Gastroenterology 2000;31:130-6. [DOI: 10.1097/00004836-200009000-00008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
9 Mégraud F, Roberts P, Williamson R. Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter. 2000;5:222-226. [PMID: 11179987 DOI: 10.1046/j.1523-5378.2000.00034.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rinaldi V, Zullo A, De Francesco V, Hassan C, Winn S, Stoppino V, Faleo D, Attili AF. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther. 1999;13:163-168. [PMID: 10102945 DOI: 10.1046/j.1365-2036.1999.00462.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 2.4] [Reference Citation Analysis]
11 Ulmer H, Beckerling A, Gatz G. Recent Use of Proton Pump Inhibitor-Based Triple Therapies for the Eradication of H. pylori: A Broad Data Review. Helicobacter 2003;8:95-104. [DOI: 10.1046/j.1523-5378.2003.00129.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
12 Van Oijen AHAM, Verbeek AL, Jansen JBMJ, De Boer WA. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies: REVIEW: RBC- OR PPI-BASED HELICOBACTER PYLORI CURE. Alimentary Pharmacology & Therapeutics 2000;14:991-9. [DOI: 10.1046/j.1365-2036.2000.00798.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
13 Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pyloriWorld J Gastroenterol 2004; 10(11): 1656-1658 [PMID: 15162544 DOI: 10.3748/wjg.v10.i11.1656] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 40] [Article Influence: 1.9] [Reference Citation Analysis]
14 Xia HH, Yu Wong BC, Talley NJ, Lam SK. Alternative and rescue treatment regimens for Helicobacter pylori eradication. Expert Opin Pharmacother. 2002;3:1301-1311. [PMID: 12186623 DOI: 10.1517/14656566.3.9.1301] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
15 Malfertheiner P, Leodolter A, Peitz U. Cure of Helicobacter pylori -associated ulcer disease through eradication. Best Practice & Research Clinical Gastroenterology 2000;14:119-32. [DOI: 10.1053/bega.1999.0063] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
16 Kamberoglou D, Polymeros D, Sanidas I, Doulgeroglou V, Savva S, Patra E, Tzias V. Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2001;15:1493-1497. [PMID: 11552924 DOI: 10.1046/j.1365-2036.2001.01072.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
17 Gisbert JP, González L, Calvet X, Roqué M, Gabriel R, Pajares JM. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. Aliment Pharmacol Ther. 2000;14:1141-1150. [PMID: 10971230 DOI: 10.1046/j.1365-2036.2000.00809.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
18 Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther. 1999;13:719-729. [PMID: 10383500 DOI: 10.1046/j.1365-2036.1999.00530.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 84] [Article Influence: 4.5] [Reference Citation Analysis]
19 Spinzi GC, Boni F, Bortoli A, Colombo E, Ballardini G, Venturelli R, Minoli G. Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. Aliment Pharmacol Ther 2000;14:325-30. [PMID: 10735926 DOI: 10.1046/j.1365-2036.2000.00708.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
20 De Francesco V, Zullo A, Hassan C, Faleo D, Ierardi E, Panella C, Morini S. Two new treatment regimens for Helicobacter pylori eradication: a randomised study. Dig Liver Dis. 2001;33:676-679. [PMID: 11785713 DOI: 10.1016/s1590-8658(01)80044-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
21 Zullo A, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, Ripani C, Tomaselli G, Attili AF. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000;14:715-718. [PMID: 10848654 DOI: 10.1046/j.1365-2036.2000.00766.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 120] [Article Influence: 5.8] [Reference Citation Analysis]
22 Taghavi SA, Jafari A, Eshraghian A. Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients. Dig Dis Sci. 2009;54:599-603. [PMID: 18594971 DOI: 10.1007/s10620-008-0374-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
23 De Francesco V, Zullo A, Hassan C, Della Valle N, Pietrini L, Minenna MF, Winn S, Monno R, Stoppino V, Morini S. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis. 2004;36:322-326. [PMID: 15191200 DOI: 10.1016/j.dld.2003.12.015] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 2.8] [Reference Citation Analysis]
24 Catalano F, Branciforte G, Catanzaro R, Cipolla R, Bentivegna C, Brogna A. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. Aliment Pharmacol Ther. 2000;14:1329-1334. [PMID: 11012478 DOI: 10.1046/j.1365-2036.2000.00839.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kuipers EJ, Klinkenberg-Knol EC. Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion. Gastroenterology. 1999;116:479-483. [PMID: 9922329 DOI: 10.1016/s0016-5085(99)70145-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
26 Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter. 2019;24:e12565. [PMID: 30698318 DOI: 10.1111/hel.12565] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
27 Pipkin GA, Williamson R, Wood JR. One-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori: REVIEW: CLARITHROMYCIN TRIPLE THERAPY. Alimentary Pharmacology & Therapeutics 1998;12:823-37. [DOI: 10.1046/j.1365-2036.1998.00405.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 3.6] [Reference Citation Analysis]
28 Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocellá L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther. 2002;16:1269-1275. [PMID: 12144576 DOI: 10.1046/j.1365-2036.2002.01244.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 2.9] [Reference Citation Analysis]